REPAIR. RESTORE. RENEW.™

SURROZEN

The Wnt Company – Targeted Regeneration

August 15, 2022

Legal Disclaimers

Forward-looking statements. This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as "will," "expect," "continue," "plan," "target," "potential," "next milestone," "future," "opportunities," "key endpoints," "near term," "outlook," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen's discovery, research and development activities, in particular its development plans for its product candidates SZN-1326, SZN-043, SZN-413 and potential future candidates, including anticipated clinical development timelines, and the potential for such product candidates to be used to treat human disease. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of Surrozen. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to existing and potential future drug candidates; Surrozen's ability to identify, develop and commercialize drug candidates; Surrozen's ability to advance its product candidates into, and successfully complete, preclinical studies and clinical studies; the effects of the ongoing COVID-19 pandemic on Surrozen's business; volatility in global economic, regulatory and market conditions, which may be adversely affected by the conflict between Russia and Ukraine; and those factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, primarily under the heading "Risk Factors," our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or the underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen's expectations, plans, or forecasts of future events and views as of the date of this presentation. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen's assessments of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

From Wnt Gene Discovery to the Clinic

Scientific Discovery

1982

1st **Wnt** gene **discovered** (Roel Nusse, Harold Varmus)

2013

Breakthrough Prize in Life Sciences awarded to Hans Clevers for **"describing the role of Wnt signaling in tissue stem cells"**

Biologic Validation

2016

Surrozen founded by The Column Group in collaboration with preeminent Wnt biologists

2017

Breakthrough Prize in Life Sciences awarded to Roel Nusse for **"pioneering research on the Wnt pathway"**

Therapeutic Transformation

2019

First Wnt modulating **antibody approved**, Amgen's Evenity (romosuzumab) for osteoporosis

2020

Publication of Surrozen's **SWAP and SWEETS** antibody platform discoveries

2022+

Surrozen **progresses targeted Wnt therapeutics** platform; **initiated FIH trials Q2'22; Published SZN-1326 preclinical data**

SURROZEN

What is Wnt Biology?

Wnt Signaling Essential to Many Cell and Tissue Types

Fundamental Signal Transduction Biology

Wnt pathway central to:

- Regulating stem cell renewal, proliferation & differentiation
- Regenerating tissue

Wnt proteins generate array of Wnt signaling critical for:

- Shaping tissues during development
- Maintaining tissue architecture
- Repairing injured tissue

Many Organs and Tissues Require Wnt signaling

SURROZEN

Surrozen – Leaders in Wnt Biology





Vision	Selectively target Wnt pathway to harness the body's own repair mechanism
Initial focus	Wnt related severe or acute diseases: GI, Liver, Ophthalmology
First in class	Proof of mechanism / biology, preclinical proof of safety with clinical trials underway for SZN-1326 and SZN-043
Lead Product Candidates	Earlier than planned initiation of two clinical trials ✓ SZN-1326: Inflammatory Bowel Disease (initiated Q2'22) ✓ SZN-043: Severe Liver Disease (Initiated Q2'22) • SZN-413: Ophthalmology
Proprietary platform	Unparalleled capabilities; demonstrated preclinical POC for several programs
Well positioned	$93M cash balance

SURROZEN

Cash balance as of 6/30/22

Our Novel Approach Overcomes Previous Challenges

Paving the Way to Targeted Antibody Regeneration

Potential first synthetic soluble Wnt mimetics

Selectivity: Target specific Fzd or cell surface receptors

Potency: Confer potency through multivalent binding

Safety: Mimic normal physiologic responses

Manufacturing: Easily manufacturable leveraging typical antibody methods with high yields

Validation of Our Prominent Role in Wnt Biology Breakthroughs

nature

Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signaling

CellPress

Development of Potent, Selective Surrogate Wnt Molecules and Their Application in Defining Frizzled Requirements

SCIENTIFIC REPORTS
nature research

Tissue-targeted R-spondin mimetics for liver regeneration

Science

Structural Basis of Wnt Recognition by Frizzled

SURROZEN

Fully Integrated, Repeatable Discovery Capabilities

Potential to Transform Patient Outcomes

Internal Capabilities

Wnt Biology Expertise

Wnt Modulating Antibody Engineering

Wnt Pathway Profiling

Scientifically Driven Strategy

Scientifically Driven Strategy
~60 R&D employees
~ 50% PhD, MDs or PhD/MDs

Focus on diseases with compelling Wnt biology

R&D opportunities for deep/broad pipeline targeting Wnt pathway

Employ models with translatability to human disease

Proprietary Technologies Enable Selective Wnt Signaling

SWAP Technology



SWEETS Technology



Mimic normal physiologic **response** (natural Wnt or natural R-spondin)

Applied in diseases with **deficient Wnt ligand** or **Wnt signaling**

Customized for each disease state

Targeted with Fzd receptor selectivity or cell specific receptors

Deep Wnt Signaling Expertise Supports Productive & Expanding R&D Pipeline

Lead Programs	Indication(s)	Research	Preclinical	Phase 1	Phase 2	Phase 3	Regulatory	Next Milestone
SZN-1326	Moderate to Severe IBD							Initiated clinical trial Q2'22
SZN-043	Severe Alcoholic Hepatitis							Initiated clinical trial Q2'22
SZN-413	Retinopathies							Nominated candidate Q1'22

Research Programs

Tissue	Indications	Discovery	Proof of Concept	Lead Candidate/s
Lung	IPF			
Lacrimal Gland	Severe Dry Eye (Sjögren's)			
Cornea	Fuchs' Dystrophy			
Lung	COPD			
Pancreas	Type 1 Diabetes			
Skin	Wound Healing			

SURROZEN

SZN-1326 – Intestine Targeted Epithelial Restoration

Mechanism Suggests Potential New Treatment Paradigm in Inflammatory Bowel Disease





SZN-1326 – Potential to Transform Treatment Paradigm in UC

Targeted antibody designed to repair epithelial barrier; induce mucosal healing

Background



Moderate to Severe Ulcerative Colitis

- Characterized by large intestine inflammation and ulcers
- Debilitating: frequent diarrhea, bloody stools, weight loss, dehydration, and anemia
- Complications from severe and chronic inflammation can become life-threatening
- SOC: Treated with anti-inflammatory agents
  - Takes months to induce remission
  - Achieve remission in < 50% and mucosal healing in < 20%
  - Fail multiple therapies

Our Solution



MOA: Designed to repair epithelial barrier & induce mucosal healing

- Dysregulation of Wnt signaling may play a role in abnormal epithelial healing in IBD
- Mucosal healing associated with better patient outcomes

Targeted: Selectively targets Fzd5 abundant in intestinal epithelium

SURROZEN

Intestine-Targeted Regeneration and Functional Improvement

Differentiated Preclinical Data

- Repairs damaged colon epithelium
- Induces mucosal healing
- Reduces inflammation
- Improves disease activity index
- Better activity than other anti-inflammatory agents including biologics
- No adverse findings in GLP tox studies

Normal
(No DSS Damage)



Damaged
(DSS Damage)





Restored
(DSS Damage + SZN-1326)



SURROZEN

SZN-1326 Phase 1 Trial Overview

Focus - Proof of Clinical Concept in Ph 1b Ulcerative Colitis
Phase 1 Trial Ongoing

Three-Part Ph 1 Randomized Trial Design

Ph 1a – SAD
Healthy volunteers

N = up to 44

Up to 5 randomized IV cohorts, and 2 SC cohorts

Ph 1a – MAD
Healthy volunteers

N = up to 24

Up to 3 randomized cohorts (IV)
Dosing for 4 doses

Ph 1b – MAD
Moderate-severe patients with UC

N= up to 24

Proof of clinical concept

Up to 3 randomized cohorts dosed IV weekly or biweekly for 12 wks. Follow-up - 24 weeks

Key Endpoints

Ph 1a SAD/MAD
- Safety
- PK/PD
- ADA

Ph 1b UC MAD
- Clinical remission and response
- Endoscopic remission
- Histologic remission
- UC-100
- PD markers

SURROZEN

Potential for First Approved Treatment for Severe Alcoholic Hepatitis

Liver Specific Wnt Activation and Regeneration



SZN-043 Potential to Transform Patient Outcomes in Severe AH

Targeted antibody designed to induce hepatocyte proliferation and improve liver function

Background

- Serious form of acute decompensated alcoholic liver disease caused by heavy alcohol use
- Leads to liver cell death, damage and subsequent inflammation
- 90-day mortality of 30%
- ~130K hospitalizations per year
- No approved treatments
  - Steroids: contra-indicated in > 50% of patients; no benefit at 3 months+
  - Liver transplants: limited supply, costly and often denied



Our Solution



MOA: SZN-043 designed to addresses underlying pathophysiology

- Hepatocyte proliferation correlated with increased survival
- Upregulation of Wnt signaling implicated in improved liver function

Targeted: Selectivity achieved through inclusion of ASGR1

SURROZEN

SZN-043 In Vivo Effects

Liver Specific Proliferation, Functional Improvement, Fibrosis Regression

Compelling Preclinical Data

- >25 preclinical studies conducted
- Selectively activates Wnt Signaling
- Induces hepatocyte proliferation
- Rapidly improves liver function
- Reduces markers of liver injury & inflammation
- No adverse findings in GLP tox studies

Improvement in Liver Function

AST:ALT ratio



Ammonia



Alcohol liver injury model

Clotting Time*



TAA model

Regression of Fibrosis

Fibrotic Area



SZN-043 V.2 in TAA Model

Fibrotic Area



Anti-GFP SZN-043



SZN-043 Phase 1 Clinical Trial Overview

Focus – Proof of Concept in Early Cirrhosis; Potential Expedited Regulatory Pathway
Phase 1 Trial Ongoing

Multi-Part Ph 1 Randomized Trial Design

Ph 1a – SAD
Healthy volunteers

N = up to 24

Up to 4 randomized cohorts (IV)

Ph 1b – SAD/MAD
Early cirrhosis

N = Up to 16

Up to 2 randomized cohorts (IV)

PD markers indicative of liver proliferation and function improvement

Ph 1b
Severe Alcoholic Hepatitis (AH)

N = up to 30

Early read on LILLE score and MELD scores – high survival correlation

Further *proof of clinical activity*; potential for Fast Track
and Breakthrough Designation

Key Endpoints

Ph 1a SAD:
- Safety, ADA
- PK/PD (including methacetin br eath test)

Ph 1b SAD/ MAD - (early cirrhosis)
- Safety
- PK/PD (including methacetin br eath test, Hepquant)
- ADA

Ph 1b Severe AH MAD
- Lille and MELD scores
- Mortality

SURROZEN

Platform Broadly Applicable Across Wide Spectrum of Diseases

Current Focus
Current Technology

Gastrointestinal/Liver
UC, Crohn's, SAH, ACLF

Ophthalmology
Wet AMD, Diabetic Retinopathy, DME, Severe Dry Eye (Sjögren's)



Future Opportunities
Current Technology

Kidney
FSGS, PKD

Lung
IPF, COPD

Neurology
MS, Stroke

Current Focus
Future Technology

Future Opportunities
Future Technology

SURROZEN

Robust Activity in Multiple Preclinical Ophthalmology Models

SZN-413 (mono Fzd 4) lead candidate for retinopathy – addresses retinal non-perfusion and vascular leakage simultaneously

Fzd4 signaling plays critical role in retinal vasculature integrity

Stimulated Wnt signaling

Increased tight junction protein expression in endothelial cells

Restored norrin function in Ndp KO mice

Reduced avascular area & pathologic NV tuft formation in OIR model; reduced vascular leakage in VEGF-induced retinal model





Lacrimal Gland (LG) Program

Tear-producing glands rely on Wnt signaling for function

Stimulated Wnt signaling

Effect observed in lacrimal and meibomian gland

Increased tear production within 2 days in IL-1a lacrimal gland model



Lung Regeneration Program

Recent Discoveries Suggest Potential Role for Wnt in Treatment of IPF and COPD

Compelling Preclinical Data

- Activates Wnt Signaling
- Expands alveolar AT2 cell organoids
- Reduced injury and improved fibrosis in the acute bleomycin model

Expands AT2 Cell Alveolar Organoids





Reduction of Fibrosis









SURROZEN

Near Term Outlook and Potential Milestones

Multiple Clinical Milestones with Potential for Early Proof of Concept

SZN-1326 Intestine	**2021** Completed IND-enabling Toxicology Studies	**Q2' 2022** Initiated Phase 1a in Healthy Volunteers [HV] (Q2'2022)	**2023** Phase 1b in Ulcerative Colitis Patients
SZN-043 Liver	**2021** Completed IND-enabling Toxicology Studies	**2022** Initiated Phase 1a in HV (Q2'2022) Initiate Phase 1b in Early Cirrhosis	**2023** Phase 1b in Severe AH Patients
SZN-413 Retinopathies		**Q1'2022** Lead Candidate	
Research Programs		**2022** Nominated Lead Candidate (SZN-413)	**2023+** Nominate Additional Lead Candidate(s) and File INDs

SURROZEN

REPAIR. RESTORE. RENEW.™

SURROZEN

The Wnt Company – Targeted Regeneration

2022

Glossary

ACLF – Acute-on-chronic liver failure–

ACTA2 – actin protein

ADA – Anti-drug antibodies

AH – Alcoholic hepatitis

ALT – Alanine Aminotransferase

AMD – Age-related macular degeneration

ASGR1 – Asiaglycoprotein receptor 1

AST – Aspartate aminotransferase

AT1/AT2 – Alveolar type epithelial cells

BW – Body weight

COPD – Chronic Obstructive Pulmonary Disease

DC – Dendritic cell

DME – Diabetic macular edema

DSS – Dextran sodium sulfate

EtOH – Ethyl alcohol

FSGS – Focal segmental glomerulosclerosis

Fzd – Frizzled

GFP – Green fluorescence protein

GI – Gastrointestinal

GLP – Good laboratory practice

HNF alpha - Hepatocyte nuclear factor 4 alpha

IBD – inflammatory Bowel Disease

IgG – Immunoglobulin G

IPF – Idiopathic pulmonary fibrosis

IND – Investigational new Drug

INR – International normalized ratio

IV – Intravenous

KO – Knock-out model

LG – Lacrimal gland

Lille – Modeling tool for predicting mortality in patients with alcoholic hepatitis who are not responding to steroid therapy

Lrp Lipoprotein receptor-related protein

MELD – Model for end-stage liver disease score

MOA – Mechanism of action

PD – Pharmacodynamics

Pg – Picogram

Mg – Milligrams

MS – Multiple sclerosis

PIPE – Private investment in public equity

PK – Pharmacokinetic

SAD – Single ascending dose

SC – Subcutaneous

MAD – Multiple ascending dose

RPE – Retinal pigment epithelium

SAH – severe alcoholic hepatitis

SOC – Standard of care

SWAP – Surrozen Wnt signal activating proteins

SWEETS – Surrozen Wnt enhancer engineered for tissue specificity

TAA – Thioacetamide

UC – Ulcerative colitis; Mod-Sev UC – Moderate to Severe UC

UC-100 – A score of a composite disease activity index for drug development in UC

VHH – Single variable domain on a heavy chain (VHH) antibodies